
Title:
Methotrexate
Text:
Chemotherapy and immunosuppressant medication


.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}"Amethopterin" redirects here. Not to be confused with Aminopterin.
.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}MethotrexateClinical dataPronunciation/ˌmɛθəˈtrɛkˌseɪt, ˌmiː-, -θoʊ-/ (listen)[1][2][3] Trade namesTrexall, Rheumatrex, Otrexup, others[4]Other namesMTX, amethopterinAHFS/Drugs.comMonographMedlinePlusa682019License data
EU EMA: by INN
US DailyMed: Methotrexate
US FDA: Methotrexate
Pregnancycategory
AU: D

Routes ofadministrationBy mouth, intravenous (IV), intramuscular (IM), subcutaneous injection (SC), intrathecalATC codeL01BA01 (WHO) L04AX03 (WHO)Legal statusLegal status
AU: S4 (Prescription only) 
CA:  ℞-only 
UK: POM (Prescription only) 
US: ℞-only 
EU: Rx-only 
In general: ℞ (Prescription only)
Pharmacokinetic dataBioavailability60% at lower doses, less at higher doses.[5]Protein binding35–50% (parent drug),[5] 91–93% (7-hydroxymethotrexate)[6]MetabolismHepatic and intracellular[5]Elimination half-life3–10 hours (lower doses), 8–15 hours (higher doses)[5]ExcretionUrine (80–100%), feces (small amounts)[5][6]Identifiersshow
IUPAC name
(2S)-2-[(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid
CAS Number59-05-2 YPubChem CID126941IUPHAR/BPS4815DrugBankDB00563 YChemSpider112728 YUNIIYL5FZ2Y5U1KEGGD00142 YChEBICHEBI:44185 YChEMBLChEMBL34259 YPDB ligandMTX (PDBe, RCSB PDB)CompTox Dashboard (EPA)DTXSID4020822 ECHA InfoCard100.000.376 Chemical and physical dataFormulaC20H22N8O5Molar mass454.447 g·mol−13D model (JSmol)Interactive imageshow
SMILES
O=C([C@H](CCC(O)=O)NC(C1=CC=C(N(CC2=CN=C(N=C(N)N=C3N)C3=N2)C)C=C1)=O)O
show
InChI
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1 YKey:FBOZXECLQNJBKD-ZDUSSCGKSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Methotrexate (MTX), formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant.[4] It is used to treat cancer, autoimmune diseases, and ectopic pregnancy and for medical abortions.[4] Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma.[4] Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn's disease.[4] It can be given by mouth or by injection.[4]
Common side effects include nausea, feeling tired, fever, increased risk of infection, low white blood cell counts, and breakdown of the skin inside the mouth.[4] Other side effects may include liver disease, lung disease, lymphoma, and severe skin rashes.[4] People on long-term treatment should be regularly checked for side effects.[4] It is not safe during breastfeeding.[4] In those with kidney problems, lower doses may be needed.[4] It acts by blocking the body's use of folic acid.[4]
Methotrexate was first made in 1947 and initially was used to treat cancer, as it was less toxic than the then current treatments.[7] In 1956 it provided the first cures of a metastatic cancer.[8] It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[9] Methotrexate is available as a generic medication.[4] In 2019, it was the 111th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[10][11]

Contents

1 Medical uses

1.1 Chemotherapy
1.2 Autoimmune disorders
1.3 During pregnancy
1.4 Administration


2 Adverse effects

2.1 Drug interactions


3 Mechanism of action
4 History
5 Research
6 References
7 External links



Medical uses[edit]
Chemotherapy[edit]
Methotrexate was originally developed and continues to be used for chemotherapy, either alone or in combination with other agents. It is effective for the treatment of a number of cancers, including breast, head and neck, leukemia, lymphoma, lung, osteosarcoma, bladder, and trophoblastic neoplasms.[4]

Autoimmune disorders[edit]
It is used as a disease-modifying treatment for some autoimmune diseases, including rheumatoid arthritis, juvenile dermatomyositis, psoriasis, psoriatic arthritis, lupus, sarcoidosis, Crohn's disease,[12] eczema and many forms of vasculitis.[13][14] Although originally designed as a chemotherapy drug (using high doses), in low doses methotrexate is a generally safe and well-tolerated drug in the treatment of certain autoimmune diseases. Because of its effectiveness, low-dose methotrexate is first-line therapy for the treatment of rheumatoid arthritis. Weekly doses are beneficial for 12 to 52 weeks duration therapy, although discontinuation rates are as high as 16% due to adverse effects.[15]  Although methotrexate for autoimmune diseases is taken in lower doses than it is for cancer, side effects such as hair loss, nausea, headaches, and skin pigmentation are still common.[13][16][17] Use of low doses of methotrexate together with NSAIDs such as aspirin or analgesics such as paracetamol is relatively safe in people being treated for rheumatoid arthritis, if adequate monitoring is done.[18]
Not everyone with rheumatoid arthritis responds favorably to treatment with methotrexate, but multiple studies and reviews showed that the majority of people receiving methotrexate for up to one year had less pain, functioned better, had fewer swollen and tender joints, and had less disease activity overall as reported by themselves and their doctors. X-rays also showed that the progress of the disease slowed or stopped in many people receiving methotrexate, with the progression being completely halted in about 30% of those receiving the drug.[19] Those individuals with rheumatoid arthritis treated with methotrexate have been found to have a lower risk of cardiovascular events such as myocardial infarctions (heart attacks) and strokes.[20]
Results of a systematic review exploring the comparative effectiveness of treatments of early rheumatoid arthritis can be improved with combination therapy of tumor necrosis factor (TNF) or non-TNF biologics with methotrexate alone.[21]
Likewise, a 2016 study found the use of methotrexate, in combination with anti-TNF agents, has been shown to be effective for the treatment of ulcerative colitis.[22]
Methotrexate has also been used for multiple sclerosis[4] and is used occasionally in systemic lupus erythematosus, with tentative evidence to support such use.[23]

During pregnancy[edit]
Methotrexate is an abortifacient and is commonly used to terminate pregnancies during the early stages, generally in combination with misoprostol. It is also used to treat ectopic pregnancies, provided the fallopian tube has not ruptured.[4][24] Methotrexate with dilation and curettage is used to treat molar pregnancy.

Administration[edit]
Methotrexate can be given by mouth or by injection (intramuscular, intravenous, subcutaneous, or intrathecal).[4] Doses are usually taken weekly, not daily, to limit toxicity.[4] Routine monitoring of the complete blood count, liver function tests, and creatinine are recommended.[4] Measurements of creatinine are recommended at least every two months.[4]

Adverse effects[edit]
The most common adverse effects include: hepatotoxicity (liver damage), ulcerative stomatitis, leukopenia and thus predisposition to infection, nausea, abdominal pain, fatigue, fever, dizziness, acute pneumonitis, rarely pulmonary fibrosis, and kidney failure.[4][13] Methotrexate is teratogenic and hence is not advised for either the prospective father to take it before or for the mother to take it before or during pregnancy (pregnancy category X) and for a period after birth.[25] Methotrexate can also cause mucositis.[26] 
Central nervous system reactions to methotrexate have been reported, especially when given via the intrathecal route (directly into the cerebrospinal fluid), which include myelopathies and leukoencephalopathies. It has a variety of cutaneous side effects, particularly when administered in high doses.[27]
Another little understood but serious possible adverse effect of methotrexate is neurological damage and memory loss.[28] Neurotoxicity may result from the drug crossing the blood–brain barrier and damaging neurons in the cerebral cortex. People with cancer who receive the medication often nickname these effects "chemo brain" or "chemo fog".[28]

Drug interactions[edit]
Penicillins may decrease the elimination of methotrexate, so increase the risk of toxicity.[4] While they may be used together, increased monitoring is recommended.[4] The aminoglycosides, neomycin and paromomycin, have been found to reduce gastrointestinal (GI) absorption of methotrexate.[29] Probenecid inhibits methotrexate excretion, which increases the risk of methotrexate toxicity.[29] Likewise, retinoids and trimethoprim have been known to interact with methotrexate to produce additive hepatotoxicity and haematotoxicity, respectively.[29] Other immunosuppressants like cyclosporins may potentiate methotrexate's haematologic effects, hence potentially leading to toxicity.[29] NSAIDs have also been found to fatally interact with methotrexate in numerous case reports.[29] Nitrous oxide potentiating the haematological toxicity of methotrexate has also been documented.[29] Proton-pump inhibitors such as omeprazole and the anticonvulsant valproate have been found to increase the plasma concentrations of methotrexate, as have nephrotoxic agents such as cisplatin, the GI drug colestyramine, and dantrolene.[29]

Mechanism of action[edit]
  The coenzyme folic acid (top) and the anticancer drug methotrexate (bottom) are very similar in structure. As a result, methotrexate is a competitive inhibitor of many enzymes that use folates.
  Methotrexate (green) complexed into the active site of DHFR (blue)
Methotrexate is an antimetabolite of the antifolate type. It is thought to affect cancer and rheumatoid arthritis by two different pathways. For cancer, methotrexate competitively inhibits dihydrofolate reductase (DHFR), an enzyme that participates in the tetrahydrofolate synthesis.[30][31] The affinity of methotrexate for DHFR is about 1000-fold that of folate. DHFR catalyses the conversion of dihydrofolate to the active tetrahydrofolate.[30] Folic acid is needed for the de novo synthesis of the nucleoside thymidine, required for DNA synthesis.[30] Also, folate is essential for purine and pyrimidine base biosynthesis, so synthesis will be inhibited. Methotrexate, therefore, inhibits the synthesis of DNA, RNA, thymidylates, and proteins.[30]
For the treatment of rheumatoid arthritis, inhibition of DHFR is not thought to be the main mechanism, but rather multiple mechanisms appear to be involved, including the inhibition of enzymes involved in purine metabolism, leading to accumulation of adenosine; inhibition of T cell activation and suppression of intercellular adhesion molecule expression by T cells; selective down-regulation of B cells; increasing CD95 sensitivity of activated T cells; and inhibition of methyltransferase activity, leading to deactivation of enzyme activity relevant to immune system function.[32][33] Another mechanism of MTX is the inhibition of the binding of interleukin 1-beta to its cell surface receptor.[34]


History[edit]
See also: History of cancer chemotherapy
  Image shows open bottle of methotrexate drug—one of the first chemotherapeutic drugs used in the early 1950s
In 1947, a team of researchers led by Sidney Farber showed aminopterin, a chemical analogue of folic acid developed by Yellapragada Subbarao of Lederle, could induce remission in children with acute lymphoblastic leukemia. The development of folic acid analogues had been prompted by the discovery that the administration of folic acid worsened leukemia, and that a diet deficient in folic acid could, conversely, produce improvement; the mechanism of action behind these effects was still unknown at the time.[35] Other analogues of folic acid were in development, and by 1950, methotrexate (then known as amethopterin) was being proposed as a treatment for leukemia.[36] Animal studies published in 1956 showed the therapeutic index of methotrexate was better than that of aminopterin, and clinical use of aminopterin was thus abandoned in favor of methotrexate.
In 1951, Jane C. Wright demonstrated the use of methotrexate in solid tumors, showing remission in breast cancer.[37] Wright's group was the first to demonstrate use of the drug in solid tumors, as opposed to leukemias, which are a cancer of the marrow. Min Chiu Li and his collaborators then demonstrated complete remission in women with choriocarcinoma and chorioadenoma in 1956,[38] and in 1960 Wright et al. produced remissions in mycosis fungoides.[39][40]

Research[edit]
In 2018, a photoactivated version of methotrexate (phototrexate) has been developed and proposed to be useful in localized, target-specific chemotherapy of psoriasis and cancer.[41]


References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"methotrexate – definition of methotrexate in English from the Oxford dictionary". OxfordDictionaries.com. Retrieved 20 January 2016.

^ "methotrexate". Merriam-Webster Dictionary.

^ "methotrexate". Dictionary.com Unabridged. Random House.

^ Jump up to: a b c d e f g h i j k l m n o p q r s t u v w "Methotrexate". The American Society of Health-System Pharmacists. Archived from the original on 8 October 2016. Retrieved 22 August 2016.

^ Jump up to: a b c d e "Trexall, Rheumatrex (methotrexate) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 8 February 2014. Retrieved 12 April 2014.

^ Jump up to: a b Bannwarth B, Labat L, Moride Y, Schaeverbeke T (January 1994). "Methotrexate in rheumatoid arthritis. An update". Drugs. 47 (1): 25–50. doi:10.2165/00003495-199447010-00003. PMID 7510620. S2CID 46974070.

^ Sneader W (2005). Drug Discovery: A History. John Wiley & Sons. p. 251. ISBN 9780470015520. Archived from the original on 16 February 2017.

^ "Today's anti-cancer tools are ever better wielded". The Economist. 14 September 2017. Retrieved 16 September 2017.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Methotrexate - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ Herfarth HH, Long MD, Isaacs KL (2012). "Methotrexate: underused and ignored?". Digestive Diseases. 30 Suppl 3: 112–8. doi:10.1159/000342735. PMC 4629813. PMID 23295701.

^ Jump up to: a b c Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.

^ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.

^ Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME (June 2014). "Methotrexate for treating rheumatoid arthritis". The Cochrane Database of Systematic Reviews (6): CD000957. doi:10.1002/14651858.CD000957.pub2. PMC 7047041. PMID 24916606.

^ Cronstein BN (June 2005). "Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis". Pharmacological Reviews. 57 (2): 163–72. doi:10.1124/pr.57.2.3. PMID 15914465. S2CID 1643606.

^ American Rheumatoid Arthritis Guidelines (February 2002). "Guidelines for the management of rheumatoid arthritis: 2002 Update". Arthritis and Rheumatism. 46 (2): 328–46. doi:10.1002/art.10148. PMID 11840435.

^ Colebatch AN, Marks JL, Edwards CJ (November 2011). "Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)". The Cochrane Database of Systematic Reviews (11): CD008872. doi:10.1002/14651858.CD008872.pub2. PMID 22071858.

^ Weinblatt ME (2013). "Methotrexate in rheumatoid arthritis: a quarter century of development". Transactions of the American Clinical and Climatological Association. 124: 16–25. PMC 3715949. PMID 23874006.

^ Marks JL, Edwards CJ (June 2012). "Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity". Therapeutic Advances in Musculoskeletal Disease. 4 (3): 149–57. doi:10.1177/1759720X11436239. PMC 3400102. PMID 22850632.

^ Donahue KE, Schulman ER, Gartlehner G, Jonas BL, Coker-Schwimmer E, Patel SV,  et al. (October 2019). "Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis". Journal of General Internal Medicine. 34 (10): 2232–2245. doi:10.1007/s11606-019-05230-0. PMC 6816735. PMID 31388915.

^ Herfarth HH (1 January 2016). "Methotrexate for Inflammatory Bowel Diseases - New Developments". Digestive Diseases. 34 (1–2): 140–6. doi:10.1159/000443129. PMC 4820247. PMID 26981630.

^ Tsang-A-Sjoe MW, Bultink IE (2015). "Systemic lupus erythematosus: review of synthetic drugs". Expert Opinion on Pharmacotherapy. 16 (18): 2793–806. doi:10.1517/14656566.2015.1101448. PMID 26479437. S2CID 36049926. ] To date, three small [86–88] RCTs in SLE patients have been published, including in total 76 patients in the active arm

^ Mol F, Mol BW, Ankum WM, van der Veen F, Hajenius PJ (2008). "Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis". Human Reproduction Update. 14 (4): 309–19. doi:10.1093/humupd/dmn012. PMID 18522946.

^ Gromnica-Ihle E, Krüger K (1 September 2010). "Use of methotrexate in young patients with respect to the reproductive system". Clinical and Experimental Rheumatology. 28 (5 Suppl 61): S80-4. PMID 21044438.

^ Oliff, A.; Bleyer, W. A.; Poplack, D. G. (1 September 1979). "Methotrexate-induced oral mucositis and salivary methotrexate concentrations". Cancer Chemotherapy and Pharmacology. 2 (3): 225–226. doi:10.1007/BF00258300. ISSN 1432-0843.

^ Scheinfeld N (December 2006). "Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions". Dermatology Online Journal. 12 (7): 15. doi:10.5070/D30NQ2C0BX. PMID 17459301.

^ Jump up to: a b Hafner DL (August 2009). "Lost in the fog: understanding "chemo brain"". Nursing. 39 (8): 42–5. doi:10.1097/01.nurse.0000358574.56241.2f. PMID 19633502.

^ Jump up to: a b c d e f g Brayfield A, ed. (6 January 2014). "Methotrexate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 12 April 2014.

^ Jump up to: a b c d Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG (October 2002). "Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics". Proceedings of the National Academy of Sciences of the United States of America. 99 (21): 13481–6. Bibcode:2002PNAS...9913481R. doi:10.1073/pnas.172501499. PMC 129699. PMID 12359872.

^ Goodsell DS (August 1999). "The molecular perspective: methotrexate". The Oncologist. 4 (4): 340–1. doi:10.1634/theoncologist.4-4-340. PMID 10476546.

^ Wessels JA, Huizinga TW, Guchelaar HJ (March 2008). "Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis". Rheumatology. 47 (3): 249–55. doi:10.1093/rheumatology/kem279. PMID 18045808.

^ Böhm I (June 2004). "Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them". Biomedicine & Pharmacotherapy. 58 (5): 338–43. doi:10.1016/j.biopha.2004.04.010. PMID 15194170.

^ Brody M, Böhm I, Bauer R (October 1993). "Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells". European Journal of Clinical Chemistry and Clinical Biochemistry. 31 (10): 667–74. CiteSeerX 10.1.1.633.8921. doi:10.1515/cclm.1993.31.10.667. PMID 8292668. S2CID 25311594.

^ Bertino JR (2000). "Methotrexate: historical aspects".  In Cronstein BN, Bertino JR (eds.). Methotrexate. Basel: Birkhäuser. ISBN 978-3-7643-5959-1.[page needed]

^ Meyer LM, Miller FR, Rowen MJ, Bock G, Rutzky J (September 1950). "Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid)". Acta Haematologica. 4 (3): 157–67. doi:10.1159/000203749. PMID 14777272.

^ Wright JC, Prigot A, Wright B, Weintraub S, Wright LT (July 1951). "An evaluation of folic acid antagonists in adults with neoplastic diseases: a study of 93 patients with incurable neoplasms". Journal of the National Medical Association. 43 (4): 211–40. PMC 2616951. PMID 14850976.

^ Hertz R, Li MC, Spencer DB (November 1956). "Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma". Proceedings of the Society for Experimental Biology and Medicine. 93 (2): 361–6. doi:10.3181/00379727-93-22757. PMID 13379512. S2CID 22939197.

^ Wright JC, Gumport SL, Golomb FM (November 1960). "Remissions produced with the use of Methotrexate in patients with mycosis fungoides". Cancer Chemotherapy Reports. 9: 11–20. PMID 13786791.

^ Wright JC, Lyons MM, Walker DG, Golomb FM, Gumport SL, Medrek TJ (August 1964). "Observations on the Use of Cancer Chemotherapeutic Agents in Patients With Mycosis Fungoides". Cancer. 17 (8): 1045–62. doi:10.1002/1097-0142(196408)17:8<1045::AID-CNCR2820170811>3.0.CO;2-S. PMID 14202592.

^ Matera C, Gomila AM, Camarero N, Libergoli M, Soler C, Gorostiza P (November 2018). "Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy". Journal of the American Chemical Society. 140 (46): 15764–15773. doi:10.1021/jacs.8b08249. hdl:2445/126377. PMID 30346152. S2CID 53043366.


External links[edit]
"Methotrexate". Drug Information Portal. U.S. National Library of Medicine.
National Rheumatoid Arthritis Society (NRAS) article on Methotrexate
Methotrexate Injection MedlinePlus article from NIH
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}show.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteIntracellular chemotherapeutic agents / antineoplastic agents (L01)SPs/MIs(M phase)Block microtubule assembly
Vinca alkaloids (Vinblastine#
Vincristine#
Vindesine
Vinflunine§
Vinorelbine#)
Block microtubule disassembly
Taxanes (Cabazitaxel
Docetaxel#
Larotaxel
Ortataxel†
Paclitaxel#
Tesetaxel)
Epothilones (Ixabepilone)
DNA replicationinhibitorDNA precursors/antimetabolites(S phase)Folic acid
Dihydrofolate reductase inhibitor (Aminopterin
Methotrexate#
Pemetrexed
Pralatrexate)
Thymidylate synthase inhibitor (Pemetrexed
Raltitrexed)
Purine
Adenosine deaminase inhibitor (Pentostatin)
Halogenated/ribonucleotide reductase inhibitors (Cladribine
Clofarabine
Fludarabine)
Nelarabine
Thiopurine (Mercaptopurine#
Tioguanine#)
Pyrimidine
Thymidylate synthase inhibitor (Capecitabine#
Carmofur
Doxifluridine
Floxuridine
Fluorouracil#
Tegafur (+gimeracil/oteracil))
DNA polymerase inhibitor (Cytarabine#)
Ribonucleotide reductase inhibitor (Gemcitabine#)
Hypomethylating agent (Azacitidine
Decitabine)
Deoxyribonucleotide
Ribonucleotide reductase inhibitor (Hydroxycarbamide#)
Topoisomerase inhibitors(S phase)I
Camptotheca (Belotecan
Camptothecin
Cositecan†
Etirinotecan pegol†
Exatecan
Gimatecan
Irinotecan#
Lurtotecan‡
Rubitecan‡
Silatecan§
Topotecan)
II
Podophyllum (Etoposide#
Teniposide)
II+Intercalation
Anthracyclines (Aclarubicin
Amrubicin†
Daunorubicin#
Doxorubicin#
Epirubicin
Idarubicin
Pirarubicin
Valrubicin
Zorubicin)
Anthracenediones (Mitoxantrone
Losoxantrone
Pixantrone)
Crosslinking of DNA(CCNS)Alkylating
Nitrogen mustards: Bendamustine#
Chlormethine
Cyclophosphamide# (Ifosfamide#
Trofosfamide)
Chlorambucil#
Melphalan (Melphalan flufenamide)
Prednimustine
Uramustine
Nitrosoureas: Carmustine
Fotemustine
Lomustine (Semustine)
Nimustine
Ranimustine
Streptozocin
Alkyl sulfonates: Busulfan (Mannosulfan
Treosulfan)
Aziridines: Carboquone
Thiotepa
Triaziquone
Triethylenemelamine
Platinum-based
Carboplatin#
Cisplatin#
Dicycloplatin
Nedaplatin
Oxaliplatin#
Satraplatin
Nonclassical
Altretamine
Hydrazines (Procarbazine#)
Mitobronitol
Pipobroman
Triazenes (Dacarbazine#
Temozolomide)
Intercalation
Streptomyces (Dactinomycin#
Bleomycin#
Mitomycins
Plicamycin)
Photosensitizers/PDT
Aminolevulinic acid
Efaproxiral
Methyl aminolevulinate
Padeliporfin
Porphyrin derivatives (Porfimer sodium
Talaporfin
Temoporfin
Verteporfin)
OtherEnzyme inhibitors
FI (Tipifarnib§)
CDK inhibitors (Abemaciclib
Alvocidib†
Palbociclib
Ribociclib
Seliciclib†)
PrI
Bortezomib
Carfilzomib
Oprozomib
Ixazomib
PhI (Anagrelide)
IMPDI (Tiazofurin§)
LI (Masoprocol)
PARP inhibitor (Niraparib
Olaparib
Rucaparib)
HDAC (Belinostat
Entinostat
Panobinostat
Romidepsin
Vorinostat)
PIKI (Pi3K) (Alpelisib
Copanlisib
Duvelisib
Idelalisib
Umbralisib)
Receptor antagonists
ERA (Atrasentan)
Retinoid X receptor (Bexarotene)
Sex steroid (Testolactone)
Other/ungrouped
Amsacrine
Arsenic trioxide
Asparagine depleters (Asparaginase#/Pegaspargase)
Belzutifan
Celecoxib
Demecolcine
Elesclomol§
Elsamitrucin
Eribulin
Estramustine phosphate
Etoglucid
Lonidamine
Lucanthone
Mitoguazone
Mitotane
Oblimersen†
Omacetaxine mepesuccinate
Trabectedin
Retinoids (Alitretinoin
Bexarotene
Tretinoin#)
Veliparib
Venetoclax

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

showvteImmunosuppressive drugs / Immunosuppressants (L04)Intracellular(initiation)Antimetabolites
purine synthesis inhibitors
Azathioprine
Mycophenolic acid
pyrimidine synthesis inhibitors
Leflunomide
Teriflunomide
antifolate
Methotrexate
Macrolides/other IL-2 inhibitors
FKBP/Cyclophilin/Calcineurin
Ciclosporin
Pimecrolimus
Tacrolimus
Voclosporin
Abetimus
Gusperimus
IMiDs
Lenalidomide
Pomalidomide
Thalidomide
PDE4 inhibitor
Apremilast
Intracellular(reception)IL-1 receptor antagonists
Anakinra
mTOR
Sirolimus
Everolimus
Ridaforolimus
Temsirolimus
Umirolimus
Zotarolimus
ExtracellularAntibodiesMonoclonalSerum target(noncellular)
Complement component 5
Eculizumab
TNF
Adalimumab
Afelimomab
Certolizumab pegol
Golimumab
Infliximab
Nerelimomab
Interleukin 5
Mepolizumab
Immunoglobulin E
Omalizumab
Interferon
Faralimomab
IL-6
Elsilimomab
IL-12 and IL-23
Lebrikizumab
Ustekinumab
IL-17A
Secukinumab
Cellulartarget
CD3
Muromonab-CD3
Otelixizumab
Teplizumab
Visilizumab
CD4
Clenoliximab
Keliximab
Zanolimumab
CD11a
Efalizumab
CD18
Erlizumab
CD20
Obinutuzumab
Rituximab
Ocrelizumab
Pascolizumab
CD23
Gomiliximab
Lumiliximab
CD40
Teneliximab
Toralizumab
CD62L/L-selectin
Aselizumab
CD80
Galiximab
CD147/Basigin
Gavilimomab
CD154
Ruplizumab
BLyS
Belimumab
CAT
Bertilimumab
Lerdelimumab
Metelimumab
Integrin
Natalizumab
Vedolizumab
Interleukin-6 receptor
Tocilizumab
LFA-1
Odulimomab
IL-2 receptor/CD25
Basiliximab
Daclizumab
Inolimomab
T-lymphocyte (Zolimomab aritox)
Unsorted
Atorolimumab
Cedelizumab
Fontolizumab
Maslimomab
Morolimumab
Pexelizumab
Reslizumab
Rovelizumab
Siplizumab
Talizumab
Telimomab aritox
Vapaliximab
Vepalimomab
Polyclonal
Anti-thymocyte globulin
Anti-lymphocyte globulin
-cept (Fusion)
CTLA-4
Abatacept
Belatacept
TNF inhibitor
Etanercept
Pegsunercept
Aflibercept
Alefacept
Rilonacept
Unsorted
Baricitinib
Blisibimod
Filgotinib
Tofacitinib
Upadacitinib

showvteSpecific antirheumatic products / DMARDs (M01C)Quinolines
Oxycinchophen
Gold preparations
Sodium aurothiomalate
Sodium aurothiosulfate
Auranofin
Aurothioglucose
Aurotioprol
Other
Penicillamine #/Bucillamine
Chloroquine #/Hydroxychloroquine
Leflunomide
Sulfasalazine #
antifolate (Methotrexate #)
thiopurine (Azathioprine) #

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

showvtePurine receptor modulatorsReceptor(ligands)P0 (adenine)
Agonists: 8-Aminoadenine
Adenine
P1(adenosine)
Agonists: 2-(1-Hexynyl)-N-methyladenosine
2-Cl-IB-MECA
2'-MeCCPA
4'-O-β-D-Glucosyl-9-O-(6''-deoxysaccharosyl)olivil
5'-N-ethylcarboxamidoadenosine
Adenosine
ADP
AMP
Apadenoson
ATL-146e
ATP
BAY 60–6583
Binodenoson
Capadenoson
CCPA
CGS-21680
CP-532,903
Evodenoson
GR 79236
LUF-5835
LUF-5845
N6-Cyclopentyladenosine
Namodenoson
Neladenoson dalanate
Piclidenoson
Regadenoson
SDZ WAG 994
Selodenoson
Sonedenoson
Tecadenoson
UK-432,097
Antagonists: 8-Chlorotheophylline
8-Phenyl-1,3-dipropylxanthine
8-Phenyltheophylline
Acefylline
Aminophylline
ATL-444
Bamifylline
Cafedrine
Caffeine
Caffeine citrate
Cartazolate
CGH-2466
CGS-15943
Choline theophyllinate
Ciforadenant
CPX
CVT-6883
Dimethazan
DMPX
DPCPX
Dyphylline
Enprofylline
Etazolate
Fenethylline
IBMX
Isovaleric acid
Istradefylline
KF-26777
MRE3008F20
MRS-1220
MRS-1334
MRS-1706
MRS-1754
MRS-3777
Paraxanthine
Pentoxifylline
Preladenant
Propentofylline
Proxyphylline
PSB-10
PSB-11
PSB-36
PSB-603
PSB-788
PSB-1115
Reversine
Rolofylline
SCH-442,416
SCH-58261
Theacrine
Theobromine
Theodrenaline
Theophylline
Tozadenant
Tracazolate
VUF-5574
ZM-241,385
P2(nucleotide)P2X(ATP)
Agonists: 2-Me-SATP
α,β-Me-ATP
Adenosine
ADP
AMP
Ap4A
Ap5A
ATP
ATPγS
BzATP
Cibacron blue
CTP
D-β,γ-Me-ATP
GTP
HT-AMP
Ivermectin
L-β,γ-Me-ATP
MRS-2219
PAPET-ATP
UTP
Zinc
Antagonists: 5-BDBD
A-317491
A-438079
A-740003
A-804598
A-839977
AF-353
AZ-10606120
AZ-11645373
BBG
Calcium
Calmidazolium
Chelerythrine
Copper
Emodin (Rheum officinale)
Evans blue
Gefapixant
GW-791343
HMA
Ip5I
isoPPADS
JNJ-47965567
KN-04
KN-62
Magnesium
MRS-2159
NF-023
NF-110
NF-157
NF-279
NF-449
Opiranserin (VVZ-149)
Oxidized-ATP
Phenol Red
Phenolphthalein
PPADS
PPNDS
PSB-12062
Puerarin (Radix puerariae)
Purotoxin 1
RB-2
Ro 0437626
Ro 51
RO-3
Sodium ferulate (Angelica sinensis, Ligusticum wallichii)
Suramin
TC-P 262
Tetramethylpyrazine (ligustrazine) (Ligusticum wallichii)
TNP-ATP
Zinc
P2Y
Agonists: 2-Me-SADP
2-Me-SATP
2-Thio-UTP
5-Br-UDP
5-OMe-UDP
α,β-Me-ATP
Adenosine
ADP
ADPβS
Ap3A
AR-C 67085MX
ATP
ATPγS
CTP
dATP
Denufosol
Diquafosol
IDP
ITP
INS-365
INS-37217
MRS-2365
MRS-2690
MRS-2693
MRS-2768
MRS-2957
MRS-4062
NF-546
PAPET-ATP
PSB-0474
PSB-1114
UDP
UDPβS
UDP-galactose
UDP-glucose
UDP-N-acetylglucosamine
Up3U
UTP
UTPγS
Antagonists: 2-Me-SAMP
A3P5PS
AMPαS
Ap4A
AR-C 66096
AR-C 67085MX
AR-C 69931MX
AR-C 118925XX
ATP
BzATP
C1330-7
Cangrelor
Clopidogrel
Elinogrel
Ip5I
MRS-2179
MRS-2211
MRS-2279
MRS-2395
MRS-2500
MRS-2578
NF-157
NF-340
PIT
PPADS
Prasugrel
PSB-0739
RB-2
Regrelor
Suramin
Ticagrelor
Ticlopidine
UDP
Transporter(blockers)CNTs
6-Hydroxy-7-methoxyflavone
Adenosine
dMeThPmR
Estradiol
KGO-2142
KGO-2173
MeThPmR
Phloridzin
Progesterone
ENTs
Barbiturates
Benzodiazepines
Cilostazol
Dilazep
Dipyridamole
Estradiol
Ethanol
Hexobendine
NBMPR
Pentoxifylline
Progesterone
Propentofylline
PMAT
Decynium-22
Enzyme(inhibitors)XO
Allopurinol
Amflutizole
Benzbromarone
Caffeic acid
Cinnamaldehyde
Cinnamomum osmophloeum
Febuxostat
Myo-inositol
Kaempferol
Myricetin
Niraxostat
Oxipurinol
Phytic acid
Pistacia integerrima
Propolis
Quercetin
Tisopurine
Topiroxostat
Others
Aminopterin
Azathioprine
Methotrexate
Mycophenolic acid
Pemetrexed
Pralatrexate
Many others
Others
Precursors: Adenine
Adenosine
AMP
ADP
ATP
Cytosine
Cytidine
CMP
CDP
CTP
Guanine
Guanosine
GMP
GDP
GTP
Hypoxanthine
Inosine
IMP
IDP
ITP
Ribose
Uracil
Uridine
UMP
UDP
UTP
Others: Chrysophanol (rhubarb)
See also: Receptor/signaling modulators
.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine
showAuthority control General
Integrated Authority File (Germany)
National libraries
United States






